AAP
ABEO icon

Arax Advisory Partners’s Abeona Therapeutics ABEO Stock Holding History

Arax Advisory Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8K Buy
+3,695
New +$20.3K ﹤0.01% 3868
2025
Q4 		– Sell
-279
Closed -$1.47K – 4072
2025
Q3 		$1.47K Buy
+279
New +$1.77K ﹤0.01% 3169

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's ABEO Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Abeona Therapeutics (ABEO) in Q2 2026: 3,695 shares worth $22.8K. The stake represents ﹤0.01% of the portfolio and ranks #3868 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ABEO as recently as Q3 2025.

Arax Advisory Partners first reported a position in ABEO in Q3 2025 and has held it in 2 quarters since. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Arax Advisory Partners held 3,695 shares of Abeona Therapeutics worth $22.8K as of Q2 2026.
  • Abeona Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Abeona Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3868 holding.
  • Arax Advisory Partners first reported a position in Abeona Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.